Srinagar Magazine

(Albany, US) DelveInsight has launched a new report on “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2030“ 

DelveInsight’s “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Colorectal Cancer (CRC), historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts:

• As per the study conducted by Fleming et al. titled “Colorectal carcinoma: Pathologic aspects” in 2011, an estimated 141,210 new cases of colorectal carcinoma were diagnosed in the United States.
• Fifty percent of all colorectal cancer patients die from metastatic disease.
• A study conducted by Marle et al. titled “Epidemiology of colorectal cancer” stated that in the United States, colorectal cancer is the third deadliest of all cancers. In 2016, there will be an estimated 134,490 new colorectal cancer cases (70,820 in males and 63,670 in females) along with 49,190 colorectal cancer deaths (26,020 and 23,170 in males and females, respectively).

 

Request for free sample page: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market

 

Scope of the report:

• The report covers the descriptive overview of Colorectal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Colorectal Cancer epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Colorectal Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Colorectal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Colorectal Cancer market

 

Request for free sample page: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market

 

Colorectal Cancer starts in the colon or the rectum. These cancers can also be named colon cancer or rectal cancer, depending on where they initiate. Most colorectal cancers start as a growth on the inner lining of the colon or rectum; these growths are called polyps. Metastatic colorectal cancer is cancer that has metastasized, which means it has spread to regional or distant sites, such as other organs or lymph nodes.

The symptoms of metastatic colorectal cancer include changes in bowel habits, diarrhea or constipation, a feeling that the bowel does not empty properly after a bowel movement, blood in feces that makes stools look black, bright red blood coming from the rectum, pain and bloating in the abdomen, fatigue or tiredness, unexplained weight loss, unexplained iron deficiency in men, or women after menopause.

Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum.

Colorectal cancer is the third leading cause of death from cancer in the United States. Most colorectal polyps are adenomas, which may develop into cancer. Though cancer can spread to any other part of the body, colorectal cancer most often spreads to the liver, lung, and peritoneum. The tumor cells can also spread to the brain and the spinal cord, which are very difficult to treat.

 

Request for free sample page: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market

 

Some of Colorectal cancer companies covered:

• Roche
• Spectrum Pharmaceutical
• Sanofi Aventis
• Genentech
• Eli Lily
• Boston Biomedical
• Surgimab
• And Many Others

Colorectal cancer Drugs covered:

• Capecitabine (Xeloda)
• Fluorouracil (5-FU)
• Oxaliplatin (Eloxatin)
• Bevacizumab (Avastin)
• Cetuximab
• Nepabucasin (BBI-608)
• SGM-101
• And Many Others

 

Request for free sample page: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Colorectal Cancer (CRC)

3. Competitive Intelligence Analysis for Colorectal Cancer (CRC)

4. Colorectal Cancer (CRC): Market Overview at a Glance

4.1. Colorectal Cancer (CRC) Total Market Share (%) Distribution in 2017

4.2. Colorectal Cancer (CRC) Total Market Share (%) Distribution in 2030

5. Colorectal Cancer (CRC): Disease Background and Overview

6. Patient Journey

7. Colorectal Cancer (CRC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Colorectal Cancer (CRC) Treatment and Management

8.2. Colorectal Cancer (CRC) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Colorectal Cancer (CRC) Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Colorectal Cancer (CRC): Seven Major Market Analysis

13.1. Key Findings

13.2. Colorectal Cancer (CRC) Market Size in 7MM

13.3. Colorectal Cancer (CRC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Colorectal Cancer (CRC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

 

Request for detailed TOC: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/colorectal-cancer-crc-market